ANIX Anixa Biosciences Inc
Company Analysis
Latest News
🟢 Anixa Biosciences is trading 5% up in after-hours trading with no clear company-specific catalyst
Anixa Biosciences is trading 5.24% higher now at $2.81 after-hours, with no clear company-specific catalyst identified. - It closed at $2.67 on October 13,...
🔴 Anixa Biosciences is trading 5% down; no clear company-specific catalyst identified
Anixa Biosciences is trading 5.28% down at $2.69, with no clear company-specific catalyst identified. - On October 13, the company announced that its ovarian...
🔴 Anixa Biosciences is trading 7.6% down in pre-market with no direct catalyst identified
Anixa Biosciences is trading 7.6% lower at $2.68 in pre-market; no direct catalyst was identified. - The October 9 close was $2.90; supplied price context...
🟢 Anixa Biosciences is trading 6.2% up in pre-market; catalyst remains unclear
Anixa Biosciences is trading 6.19% up at $3.09 in pre-market on October 9, 2026, with no clear catalyst identified. - The October 8 close was $2.91; supplied...
Anixa Reports First 3-Month Stable Disease in Ovarian Cancer CAR-T Trial
Anixa Biosciences said the first patient treated in the fifth and highest-dose cohort of its Phase 1 trial for recurrent ovarian cancer has had stable disease...
🔴 Anixa Biosciences is trading 11.86% down in pre-market; cause remains unclear
Anixa Biosciences is trading 11.86% lower at $2.60, with the cause of the October 5 pre-market decline unclear. - Shares are down from the October 2 close of...
🟢 Anixa Biosciences is trading 5.6% up today amid gains across major indexes
Anixa Biosciences is trading 5.6% higher at $2.92, with broader market strength potentially supporting shares. - The S&P 500 is up 0.71%, the NASDAQ Composite...
🟢 Anixa Biosciences is trading 6.9% up in after-hours trading amid highest-dose ovarian cancer CAR-T cohort update
Anixa Biosciences is trading 6.91% higher after hours at $2.96; the trial update may be a catalyst, though no source directly linked it to the move. - Shares...
🔴 Anixa Biosciences is trading 5% down today
Anixa Biosciences is trading 5.12% down at $2.78, with no clear catalyst established. - On October 1, 2026, the company said a second patient had been treated...
🟢 Anixa Biosciences is trading 13% up in pre-market — catalyst remains unclear
Anixa Biosciences is trading at $3.31, up 13.06% in pre-market on October 1, with no clear catalyst identified. - This compares with the September 30 close of...
🔴 Anixa Biosciences is trading 5.38% down today after H.C. Wainwright cut its price target
Anixa Biosciences is trading 5.38% down at $2.64 after H.C. Wainwright lowered its price target to $6 from $7 while maintaining a Buy rating on September 23,...
🟢 Anixa Biosciences is trading 5.4% up in pre-market as biotech sector strengthens
Anixa Biosciences is trading 5.4% higher at $2.94 in pre-market, alongside broader biotechnology-sector strength. - XBI was up 2.61% pre-market. - No new...
🟢 Anixa Biosciences is trading 7.5% up in after-hours trading; catalyst remains unclear
Anixa Biosciences is trading up 7.5% at $3.00 after hours, with the catalyst unclear. - No new company-specific announcement, earnings release, or clearly...
🟢 Anixa Biosciences is trading 5.19% up today after positive breast-cancer vaccine Phase 1 data
Anixa Biosciences is trading 5.19% up at $2.73 after positive breast-cancer vaccine Phase 1 data. - The company is advancing its breast-cancer vaccine toward...
🟢 Anixa Biosciences is trading 8% up in pre-market after positive breast-cancer vaccine Phase 1 data
Anixa Biosciences is trading 7.69% higher at $2.80 after positive breast-cancer vaccine Phase 1 data, survival observations from its ovarian-cancer CAR-T...
Anixa's Cancer Data Sparks a 7% Rally, but Can a $100 Million Biotech Survive the Long Road to Phase 2?
Shares of Anixa Biosciences jumped 7.3% to $2.79 on September 16 after the tiny cancer-focused biotech dropped a batch of positive clinical updates and a...
🟢 Anixa Biosciences is trading 7.31% up in after-hours trading after positive breast cancer vaccine data
Anixa Biosciences is trading 7.31% up in after-hours trading at $2.79 following positive breast cancer vaccine Phase 1 data and encouraging survival...
🟢 Anixa Biosciences is trading 6.88% up in after-hours trading after encouraging early cancer-program data
Anixa Biosciences is trading 6.88% up in after-hours trading at $2.95 after September 11, 2026, presentations highlighted encouraging early data from its...
Anixa's Nasdaq Summit Pitch Lifts Shares 7% — But Can a Conference Presentation Move the Needle for a $100M Biotech With No Revenue?
Shares of Anixa Biosciences jumped 7.3% to $3.11 on Sept. 9, bucking a weak broader market, as investors positioned ahead of CEO Amit Kumar's afternoon...
🟢 Anixa Biosciences is trading 7.34% up in pre-market ahead of September 9 clinical-program presentation
Anixa Biosciences is trading 7.34% up now at $3.11 after announcing a September 9 presentation at the Nasdaq & LD Micro Inaugural SF Summit. - Management is...